The Board of Directors of BeyondSpring Inc. appointed Dr. Jiangwen Majeti and Mr. Sihai Xu to the Board, effective immediately. Dr. Majeti is an investor, biotech company advisor, and an executive with more than twenty years of experience in the biotech and pharmaceutical industry. Most recently, she was the Head of Global Collaborations and General Manager, China of Erasca Inc. Prior to that, she was Global Category Leader for Roche External Alliance. She is the past president and currently serves on the board of directors of the Chinese-American Biopharmaceutical Society.

She is also a member of the BayHelix Group. Dr. Majeti earned her Ph.D. from the University of Wisconsin at Madison and obtained her postdoctoral training at the Howard Hughes Medical Institute of the University of California, San Francisco. She also earned an MBA from the Leavey School of Business at Santa Clara University, graduating as a member of the Beta Gamma Sigma Honor Society.

She completed her undergraduate studies in Biochemistry at Fudan University in China. Mr. Xu has been an accomplished financial executive for almost thirty years. Mr. Xu currently serves as the Chief Financial Officer and on the board of directors of BOJI Health Investment Management (Shanghai) Co.

Ltd., which he joined in 2014. Previously, he was the Chief Financial Officer of Henan Plastic Surgery Hospital, the Chief Financial Officer of Shanghai BOJI Hospital Investment Management Co. Ltd., and the Chief Financial Officer of Henan Zhiyi Investment Management Co.

Ltd. As financial advisor and strategic investor, Mr. Xu have participated in pre-IPO, IPO, and major asset restructuring for dozens of public companies in China and Hong Kong. Mr. Xu received his MBA from Renmin University of China and his Bachelor's Degree in Financial Accounting from Henan University of Economics and Law in China.